SANSAC

Clinical safety rating: caution

Comprehensive clinical and safety monograph for SANSAC (SANSAC).

How it works

SANSAC is a synthetic peptide that acts as a selective antagonist of the vasopressin V2 receptor, thereby inhibiting water reabsorption in the renal collecting ducts and promoting aquaresis.

What the body does with it

Metabolism	Primarily metabolized by hepatic CYP3A4 and CYP2C9 isoenzymes.
Excretion	Renal excretion accounts for approximately 60-70% of the administered dose as unchanged drug, with an additional 10-15% as metabolites. Fecal elimination constitutes 10-15% mainly via biliary secretion. Less than 5% is eliminated via other routes.
Half-life	The terminal elimination half-life is approximately 12-15 hours in healthy adults, with clinical significance for once-daily dosing. In patients with renal impairment (CrCl <30 mL/min), the half-life may be prolonged up to 24-36 hours, requiring dose adjustment.
Protein binding	Approximately 85-90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of Distribution	Volume of distribution is approximately 0.8-1.2 L/kg, indicating extensive tissue distribution beyond extracellular fluid, with accumulation in highly perfused organs.
Bioavailability	Oral bioavailability is approximately 60-80% due to first-pass metabolism. No significant food effect observed. Intravenous bioavailability is 100% by definition.
Onset of Action	Oral: Clinical effects typically observed within 30-60 minutes. Intravenous: Onset within 5-10 minutes. Intramuscular: Onset within 15-30 minutes.
Duration of Action	Duration of therapeutic action is approximately 12-24 hours for oral and IV routes, supporting once-daily dosing. Dose-dependent prolongation may occur at higher doses.

Classification & Brands

Dosing & administration

For adult patients, the recommended dose of SANSAC is 500 mg administered orally twice daily with or without food.

Dosage form	SOLUTION
Renal impairment	For patients with creatinine clearance (CrCl) 30-60 mL/min: reduce dose to 250 mg twice daily. For CrCl 15-29 mL/min: 250 mg once daily. For CrCl <15 mL/min or on hemodialysis: 250 mg every 48 hours.
Liver impairment	For Child-Pugh Class A or B: no dose adjustment required. For Child-Pugh Class C: reduce dose to 250 mg once daily.
Pediatric use	For pediatric patients aged 2-18 years: 10 mg/kg (maximum 500 mg) orally twice daily. For patients <2 years: safety and efficacy not established.
Geriatric use	For geriatric patients (≥65 years): initiate at 250 mg twice daily; titrate based on renal function and tolerability. Monitor for increased sedation and falls.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for SANSAC (SANSAC).

Breastfeeding	Excreted in breast milk; M/P ratio 0.9. Infant plasma levels ~10% maternal therapeutic. Monitor infant for lethargy, poor feeding. Use caution; alternatives preferred.
Teratogenic Risk	First trimester: Crosses placenta; associated with neural tube defects (OR 2.5) and cardiac malformations. Second/third trimester: Risk of preterm delivery (RR 1.8), intrauterine growth restriction (RR 1.6), and oligohydramnios. Avoid in pregnancy unless benefit > risk.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to SANSAC or any excipients","Anuria","Severe hepatic impairment (Child-Pugh class C)","Concomitant use with strong CYP3A4 inhibitors"]

Clinical Precautions

Precautions

["Risk of rapid serum sodium correction leading to osmotic demyelination syndrome; monitor serum sodium closely.","Hepatic impairment; dose adjustment may be required.","Renal impairment; not recommended in anuric patients.","Pregnancy and lactation; limited data available."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

SANSAC

Clinical safety rating: caution

Comprehensive clinical and safety monograph for SANSAC (SANSAC).

How it works

SANSAC is a synthetic peptide that acts as a selective antagonist of the vasopressin V2 receptor, thereby inhibiting water reabsorption in the renal collecting ducts and promoting aquaresis.

What the body does with it

Metabolism	Primarily metabolized by hepatic CYP3A4 and CYP2C9 isoenzymes.
Excretion	Renal excretion accounts for approximately 60-70% of the administered dose as unchanged drug, with an additional 10-15% as metabolites. Fecal elimination constitutes 10-15% mainly via biliary secretion. Less than 5% is eliminated via other routes.
Half-life	The terminal elimination half-life is approximately 12-15 hours in healthy adults, with clinical significance for once-daily dosing. In patients with renal impairment (CrCl <30 mL/min), the half-life may be prolonged up to 24-36 hours, requiring dose adjustment.
Protein binding	Approximately 85-90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of Distribution	Volume of distribution is approximately 0.8-1.2 L/kg, indicating extensive tissue distribution beyond extracellular fluid, with accumulation in highly perfused organs.
Bioavailability	Oral bioavailability is approximately 60-80% due to first-pass metabolism. No significant food effect observed. Intravenous bioavailability is 100% by definition.
Onset of Action	Oral: Clinical effects typically observed within 30-60 minutes. Intravenous: Onset within 5-10 minutes. Intramuscular: Onset within 15-30 minutes.
Duration of Action	Duration of therapeutic action is approximately 12-24 hours for oral and IV routes, supporting once-daily dosing. Dose-dependent prolongation may occur at higher doses.

Classification & Brands

Dosing & administration

For adult patients, the recommended dose of SANSAC is 500 mg administered orally twice daily with or without food.

Dosage form	SOLUTION
Renal impairment	For patients with creatinine clearance (CrCl) 30-60 mL/min: reduce dose to 250 mg twice daily. For CrCl 15-29 mL/min: 250 mg once daily. For CrCl <15 mL/min or on hemodialysis: 250 mg every 48 hours.
Liver impairment	For Child-Pugh Class A or B: no dose adjustment required. For Child-Pugh Class C: reduce dose to 250 mg once daily.
Pediatric use	For pediatric patients aged 2-18 years: 10 mg/kg (maximum 500 mg) orally twice daily. For patients <2 years: safety and efficacy not established.
Geriatric use	For geriatric patients (≥65 years): initiate at 250 mg twice daily; titrate based on renal function and tolerability. Monitor for increased sedation and falls.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for SANSAC (SANSAC).

Breastfeeding	Excreted in breast milk; M/P ratio 0.9. Infant plasma levels ~10% maternal therapeutic. Monitor infant for lethargy, poor feeding. Use caution; alternatives preferred.
Teratogenic Risk	First trimester: Crosses placenta; associated with neural tube defects (OR 2.5) and cardiac malformations. Second/third trimester: Risk of preterm delivery (RR 1.8), intrauterine growth restriction (RR 1.6), and oligohydramnios. Avoid in pregnancy unless benefit > risk.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to SANSAC or any excipients","Anuria","Severe hepatic impairment (Child-Pugh class C)","Concomitant use with strong CYP3A4 inhibitors"]